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Summary  
Background 
Clopidogrel is an antiplatelet drug, blocking the ADP-pathway of platelet activation. 
Currently there is no universally accepted definition of clopidogrel non- responsiveness. 
The difference between pre-treatment and posttreatment ADP- induced platelet aggregation 
has been used as an estimate of clopidogrel non- responsiveness. 
The aim of the present study was to define a cut- off point for clopidogrel non- responsiveness 
in a study population of patients with stable coronary heart disease (CHD), and possibly give 
an estimation of the prevalence of non- responders in patients with stable CHD. 
Methods 
The study population consists of 227 consecutively enrolled patients from the ASCET-study, 
all treated with ASA, of which 91 were later randomized to clopidogrel. Analysis on venous 
blood samples were performed using VerifyNow P2Y12 assay, which measures ADP-induced 
platelet aggregation. We performed descriptive statistics on the outcome. 
Results 
The 5% percentile of Platelet Reaction Units (PRU) at baseline was close to 170, and we used 
this as our cut- off- point for non- responsiveness. The equivalent 95% percentile value in % 
inhibition was 24%. After one month on clopidogrel treatment, we calculated a prevalence of 
non- responsiveness to clopidogrel of 35% and 28% for PRU and % inhibition respectively.  
Conclusions 
We found a frequency of clopidogrel non- responsiveness (28-35%) that corresponds with 
current literature (5-44%). As ex vivo platelet function tests not necessarily give an accurate 
measurement of in vivo platelet function, clinical non- responsiveness needs to be explored in 
larger prospective studies. 
 3
Introduction/ background  
Platelet aggregation plays a major role in the pathogenesis of cardiovascular disease. Before 
clopidogrel was introduced, acetylsalisylic acid (ASA) was the generally used antiplatelet 
drug for long term treatment. ASA is an irreversible cyclooxygenase 1- inhibitor. 
In general clopidogrel is an antiplatelet drug, blocking the ADP-pathway of platelet 
activation. Clopidogrel (Plavix®) is used for prevention of atherotrombotic events in patients 
with acute coronary syndrome (unstable angina pectoris or acute myocardial infarction) and in 
patients undergoing Percutaneous Coronary Intervention (PCI) with stenting of coronary-, 
carotic-, intestinal or kidney arteries. The costs for up to nine months treatment in 
combination with ASA after PCI for acute myocardial infarction, are covered by 
Rikstrygdeverket/ NAV trygd.   
 
The ADP- pathway of platelet aggregation 
Basic intracellular signalling pathways: 
Circulating platelets are activated when being exposed to collagen and/ or von Willebrand 
factor at the site of a plaque rupture or endothelial fissures. 
Activation of platelets results in the release of two major soluble agonists, tromboxane A2, 
which is produced from membrane phospholipids (arachidonic acid) by cyclo-oxygenase 1/ 
thromboxane syntethase enzymes, and ADP released from dense granules. There are two G- 
coupled protein receptors for the ADP- induced platelet activation: P2Y12 and P2Y1(1), 
respectively mediating adenylcyclase inhibition and mobilization of intracellular calcium 
stores (2). Activation of both receptors is needed for complete aggregation (1).  
 
A description of the intricate intracellular pathways following ADP binding to the P2Y 
receptors is in short (Figure 1): 
P2Y1 is coupled to the Gq protein. The intracellular signalling pathways activate the 
phospholipase C, resulting in mobilization of intracellular calcium. This initiates a series of 
events resulting in platelet shape change and weak aggregation in response to ADP. This 
reseptor has a crucial role in the initiation of platelet activation induced by ADP or collagen 
(3).  
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 The P2Y12 receptor is responsible for the completion of the platelet aggregation in response to 
ADP. It plays a central role in amplification of the aggregation induced by all known platelet 
agonists, whatever their signalling pathway. And it sustains and stabilises a forming thrombus 
(3).  
 
The P2Y12 receptor is linked to the Gi protein. Normally, intact endothelium secretes 
prostacyclin that activates adenylcyclase and increases platelet cAMP levels. However, 
activation of the P2Y12 receptor inhibits adenylcyclase activity and thereby decrease cAMP 
levels. A reduction in cAMP lower the activity of cAMP-dependant protein kinases which in 
turn, reduce the levels of phosphorylated vasodilator stimulated phoshoprotein (VASP), and 
reduces its protective effect on the activation of the GP IIb/IIIa receptor.  
Flowcytometric analysis of VASP phosphorylation has been used as a test of P2Y12 activity 
and clopidogrel resistance.  
In summary: Activation of the P2Y12 receptor results in a cascade of intracellular signalling 
events that take part in the final activation of the GP IIb/IIIa receptor, the amplification of 
platelet aggregation, the facilitation of granule release, and the stabilization of the platelet 
aggregate (2). 
 
Clopidogrel metabolism: 
Clopidogrel is a pro- drug being absorbed from the intestine and transported into the blood 
stream. In the liver the pro-drug is excessively converted by the hepatic cytochrom P450 
isoenzymes (CYP3A4, CYP3A5 and 2C19). About 85% of the drug is hydrolyzed by 
esterases to an inactive carboxylic acid derivative. However a small fraction is converted into 
the intermediate metabolite 2-oxo-clopidogrel by cytochrome P450 monooxygenase. The 
instable 2-oxo-clopidogrel is non-enzymatically hydrolyzed to the active thiol metabolite that 
irreversibly binds to the cystein residues (cys17 and cys270) on the platelet P2Y12 receptor 
resulting in a partial inhibition of the platelet aggregation, (1), (2), (4), (5), (6). 
 
Mechanisms of clopidogrel: 
The disulphide bridge between the thiol metabolite of clopidogrel and the cystein residues on 
the P2Y12 receptor results in the effective blockade of ADP-induced platelet activation and 
aggregation. Through the ADP-blockade, clopidogrel also inhibits the expression of P-selectin 
and CD40 ligand, preventing the formation of heterotypic aggregates and induction of 
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inflammation. It is important to bear in mind that clopidogrel only partly inhibit the ADP 
activating pathway.  
Although a platelet inhibitory effect has been detected in healthy volunteers as early as two 
hours after a 75mg dose of clopidogrel, a steady-state of inhibition (50-60%) was reached 
only after repeated administration of a daily dose of 75mg for 5-7 days (1). A loading dose 
between 300 and 600mg clopidogrel will help achieve steady-state faster, and is often used in 
clinical practise. (1).  
 
 
Figure 1. Adenosine diphosphate (ADP) and the P2Y12 receptor. Activation of the P2Y12 receptor by ADP liberates the Gi 
protein subunits αGi and Bγ. αGi inhibits adenylyl cyclase (AC) decreasing platelet cyclic adenosine monophosphate (cAMP) 
levels with the consequent reduction in protein kinase (PKA) phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP-P). This results in a decrease in VASP-P inhibition of glycoprotein IIb/IIIa (GP IIb/IIIa), with the consequent GP 
IIb/IIIa activation and resultant platelet aggregation. Subunit Bγ activates phosphoinositol 3-kinase (PI 3K) and 
phosphotyrosine kinases (Pt K) linked to GP IIb/IIIa activation and platelet dense granule secretion. PLC: phospholipase C; 
ATP: adenosine triphosphate. Oqueli et al. Clopidogrel resistance. Heart, Lung and Circulation 2007. 
 
Clopidogrel non- responsiveness 
Currently there is no universally accepted definition of clopidogrel non- responsiveness, also 
called clopidogrel resistance, clopidogrel low responsiveness or hyporesponsiveness. 
Clopidogrel non- responsiveness will be the used term for the following.  
In its broadest sense, non- responsiveness could refer to continued occurrence of ischemic 
events in spite of antiplatelet therapy with compliance. Gurbel et al define non- 
responsiveness as failure of the antiplatelet agent to inhibit the target of its action (6). 
Clopidogrel non- responsiveness might therefore be best demonstrated by evidence of residual 
 6
post- treatment P2Y12 activity by measuring ADP- induced platelet aggregation before and 
after treatment, although ADP is not specific for P2Y12- receptor activation.  
 
The difference between pretreatment and posttreatment ADP- induced platelet aggregation 
has been used as an estimate of clopidogrel non- responsiveness (2), (7), (8), (9), (10). 
Clopidogrel non- responsiveness has in some studies (7), (8), (9) been defined as an absolute 
difference between baseline aggregation and posttreatment aggregation of 10% or less with 5 
μmol/L ADP used as agonist, tested by turbidimetric platelet aggregometry. This is an in vitro 
evaluation of platelet aggregation, and the importance of this laboratory phenomenon on 
clinical endpoints is not yet established.   
Current estimates on the frequency of clopidogrel non- responsiveness are between 5- 44% 
(6).  
 
Platelet function testing 
Current standard for platelet function testing is turbidimetric platelet aggregometry, despite of 
poor reproducibility, high sample volume, need of sample preparation, need of technicians, 
time, expense etc. New point- of- care tests for platelet function have been developed 
including VerifyNow (Accumetrics, San Diego, CA) and PFA-100 (Dade behring, Newark, 
DE) (10), (11).  
 
Clopidogrel non- responsiveness: possible mechanisms   
Non- compliance, and under- dosing or inappropriate dosing of clopidogrel are possible 
mechanisms of non- responsiveness. There are different opinions regarding the optimal 
loading and maintenance dose regimens. Several studies have shown that a 600 mg loading 
dose of clopidogrel gives a superior antiplatelet effect than a 300 mg loading dose for patients 
undergoing coronary stenting (8), (12). In the study of Gurbel et al, (8), the aim of study was 
to determine the effect of clopidogrel dosing on the incidence of non- responsiveness and high 
posttreatment platelet aggregation. They defined clopidogrel non- responsiveness as a < 10% 
change in aggregation (baseline aggregation minus posttreatment aggregation). In the 600 mg 
group, they had lower post treatment platelet aggregation, greater change in aggregation, and 
a lower percentage of non- responders compared to the 300mg group. They concluded that 
estimates of non- responsiveness are dose- dependent. In the ISAR- CHOICE study, (12), a 
loading dose of 900mg clopidogrel compared to a 600mg loading dose showed no further 
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increase in plasma concentrations of active metabolite, and no further suppression of ADP- 
induced platelet aggregation.  
 
Failure of metabolization of clopidogrel into an active metabolite in the liver by CYP 3A4 
could be the mechanism of non- responsiveness to the drug.  
This can be caused by a variability in the phenotypic expression of hepatic CYP 3A4 (2),(13) 
and also by genetic polymorphisms of the CYP3A4 gene (14). 
It can also be caused by drug- drug interactions. Many drugs are metabolized by CYP 3A4. 
Any drugs inhibiting or being a substrate of the CYP3A4 can potentially block the conversion 
of clopidogrel into its active metabolite (14). Atorvastatin is one of these drugs. Some studies 
have shown that atorvastatin do influence the level of clopidogrel induced platelet inhibition, 
other studies have concluded that this interaction is not clinically relevant (15). Schroeder et 
al sum up some of the studies on clopidogrel and HMG-CoA reductase inhibitors’ interaction 
(16). An in vitro interaction between a CYP 3A4 substrate statin and clopidogrel has been 
shown, but the clinical relevance of this interaction has not been recognised. Studies point in 
this direction, but sample size makes it non- statistically significant. Their conclusion is that 
further prospective studies on the hard clinical events are needed (16).  
Erythromycin is another drug that compete with clopidogrel for CYP3A4 metabolism. 
Whether the drug rifampin and the herb St. John’s wort enhance the inhibitory effect of 
clopidogrel by induction of the CYP 3A4 gene remains questionable (2), (6).  
Impaired or variable gastrointestinal absorption of the prodrug is another possible mechanism 
of non- responsiveness.    
 
Fontana et al argues that there is a large variability in the number of P2Y12 receptors in 
individuals, and questions whether genetic variability of the P2Y12 receptor could be a 
mechanism of non- responsiveness. Two haplotypes of the P2Y12 receptor gene have been 
identified, the H1 and H2 haplotypes. The H2 haplotype is associated with maximal platelet 
aggregation in response to ADP, and therefore carriers with an increased number of  the ADP 
P2Y12- receptors associated with the H2 haplotype may have an increased risk of 
atherothrombosis and/ or a lesser clinical response to antiplatelet drugs (17).  
Variability in the downstream intracellular signalling, or alternate pathways of platelet 
activation have also been suggested as mechanisms for non- responsiveness.  For example by 
the increased extent of P2Y1 receptor- dependent platelet aggregation or up- regulation of 
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other pathways of platelet activation (thrombin, thromboxane A2, collagen) (3), or yet another 
possibility: increased reactivity of resting platelets and high pretreatment platelet reactivity.  
 
Present study 
Aim of study  
The aim of the present study was to define a cut off point for clopidogrel non- responsiveness 
in a study population of patients with stable coronary heart disease (CHD), and possibly give 
an estimation of the prevalence of non- responders in patients with stable CHD, evaluated by 
the recently developed method VerifyNow.  
 
Methods 
Study design 
The patients were part of the Aspirin non- responsiveness and clopidogrel clinical endpoint 
trial (ASCET) which is a prospective randomized study primarily investigating aspirin non-
responsiveness in relation to clinical events (18). Patients of both sexes with stable CHD 
verified with coronary angiography were before randomization given aspirin 160mg/d for at 
least one week (n= 227). They were then randomized to either continuing aspirin 160 mg 
daily or change to clopidogrel (Plavix®, Sanofi Winthrop Industries, Ambarese, France and 
Bristol-Myers Squibb, Paris, France) 75 mg daily. Both dosages are in accordance with 
current guidelines. Randomization was performed according to a computer- generated 
randomization list indicating the treatment allocation for each patient, developed by the 
Center for Clinical Research, Ullevål University Hospital, Oslo, Norway. Consecutively 
numbered sealed envelopes, containing treatment modality according to the randomization 
list, were used. Patients continued all other medication according to general guidelines. 
The present investigation is based on a subpopulation of 227 consecutive enrolled patients of 
which 91 were randomized to clopidogrel.  
 
Laboratory methods (VerifyNow)  
At randomization standard baseline blood sampling was performed, at 8- 10 AM, in fasting 
condition without any medication by venipuncture (Vacutainer tubes containing 3,2% sodium 
citrate in dilution 1:10 (Gruner Bio- One GmbH, Kremsmünster, Austria)), and the samples 
were tested with VerifyNow P2Y12 (n = 227). After 1 month patients randomized to 
clopidogrel treatment were retested with the VerifyNow P2Y12 assay (n= 91). 
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The VerifyNow P2Y12 Assay (Accumetrics, San Diego, CA) is designed to measure platelet 
P2Y12 receptor blockade. It is developed to measure responsiveness to P2Y12 receptor 
antagonists such as clopidogrel and prasugrel (19),(20). The VerifyNow system is a 
turbidimetric based optical detection system. It measures platelet- induced aggregation. The 
assay is based on the ability of activated platelets to bind fibrinogen. It contains microbeads 
coated with fibrinogen, aggregating in whole blood in proportion to platelet GPIIb/IIIa 
receptor expression, which increases when platelets are activated. The VerifyNow P2Y12 
assay uses ADP and PGE1 as activators of platelets in one assay channel (the ADP channel). 
In adding PGE1, the ADP- induced P2Y1- mediated platelet activation is suppressed.  
Light transmittance increases when platelets bind and aggregate the fibrin- coated 
microparticles (the light transmittance is dependent on number of particles, not their size). 
The instrument measures the change in optical signal in PRU (Platelet Reaction Units). In 
addition to ADP/PGE1, a second activator (iso- TRAP or Thrombin Receptor Activation 
Peptide) and fibrinogen- coated microparticles are incorporated into a second channel of the 
assay device. The aggregation of platelets induced by iso- TRAP occur independent of the 
P2Y12 receptors. The TRAP channel gives a measure of the baseline platelet function, BASE 
result. The BASE result is an estimate of the baseline platelet function. The results from both 
channels in the device are used to calculate percent inhibition in the sample. Percent inhibition 
is calculated as follows: % inhibition = ((BASE-PRU) x 100)/ BASE. The results given by the 
P2Y12- assay can therefore be reported as both PRU- and % inhibition (19, 22). 
 
Statistics 
We performed individual statistics for the parameters PRU and % inhibition using the SPSS 
software, version 14.0. Only descriptive statistics were used.  
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Results  
Patient characteristics at baseline 
By a randomized selection of n≈ 200 from the ASCET study population, only few significant 
differences between the two groups were recorded at baseline, see table 1 (23). There were 
more frequent hypertension in the clopidogrel group (p= 0.04) and a greater number of PCI 
treated patients in the aspirin group (p=0.04). In accordance with current guidelines 98% were 
on statin therapy. About 20% were current smokers and 20% had known diabetes mellitus 
type II. 
  
Table 1: Characteristics of a selection of the ASCET- study population at baseline. Proportion 
or median values (25, 75 percentiles) are given.  
 Aspirin 160mg (n=105)  Clopidogrel 75mg (n=101) 
Age, years 62 (56, 69)  61 (52, 79) 
Sex, % female  22 19 
Hypertension %1 48 60 
Diabetes % 18 20 
Smokers % 19 20 
BMI kg/m2 27.5 (24.8, 31.2) 27.5 (25.2, 29.3)  
Previous AMI % 53 50 
Previous PCI %1 46 33 
SBP/DBP mmHg 140/85 140/85 
Previous ACB % 25 16 
Total cholesterol mM 4.6 (4.2, 5.3) 4.4 (4.0, 5.3) 
LDL cholesterol mM 2.7 (2.2, 3.2) 2.5 (2.1, 3.0)  
HDL cholesterol mM 1.2 (1.1, 1.5) 1.2 (1.1, 1,5) 
Triglycerides mM 1.3 (0.9, 1.9)  1.4 (0.9, 1.9)  
Medication  
Aspirin % 100 100  
Clopidogrel % 0 0 
ACE-I % 29 37 
AII antagonist % 22 21 
β-blocker % 82 77 
Ca- blocker % 31 35 
Statin % 97 98  
BMI: body mass index, AMI: acute myocardial infarction, PCI: percutaneous coronary intervention, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, ACB: aortocoronar bypass, ACE-I: angiotensin- 
converting enzyme inhibitor, AII antagonist: angiotensin II receptor antagonist, β- blocker: beta- adrenergic 
receptor blocker, Ca- blocker: calsium- channel blocker. 1p=0.04 for difference between groups.   
 
 11
Baseline results 
227 patients were tested with the VerifyNow P2Y12 assay at baseline, for 5 of the patients 
results are missing due to failure of analysis (error).  
 
% inhibition results  
Table2: distribution of results 
N Valid 222
Missing 5
Mean 7,97
Median 6,00
Std. Deviation 7,949
Percentiles  25 ,00
50 6,00
75 13,00
95 23,70
 
Expected values of inhibition of the P2Y12-reseptor at baseline were low, close to zero as all 
patients were on aspirin and not on treatment with clopidogrel at this point. 
Median value was 6, which indicated that the majority of the patients had no inhibition, as 
anticipated.  95% of the patients had 24% inhibition or less of the P2Y12- receptors as shown 
in the 95 percentile. We chose this to be our cut-off value. The distribution is also shown in 
fig 2, the cut off level indicated with an arrow. 
40200
% inhib1
60
40
20
0
Fr
eq
ue
nc
y
Mean =7,97
Std. Dev. =7,949
N =222
Histogram
 
Fig 2 
 12
PRU- results 
Table 3a: Distribution of results  
N Valid 222
Missing 5
Mean 243,69
Median 240,00
Std. Deviation 45,211
Percentiles 25 212,00
50 240,00
75 276,50
95 316,85
 
Table 3b 
    Percentiles 
    5 10 25 50 75 90 95 
Weighted 
Average(Definition 1) 
PRU 1 
168,75 184,00 212,00 240,00 276,50 299,70 316,85
Tukey's Hinges PRU 1   212,00 240,00 276,00   
Expected values of platelet reactivity (measured in units) in persons non-inhibited (not on 
clopidogrel treatment) are high.  
The median value was 240. The 5% percentile of PRU was approximately 170, see table 3b. 
We defined a PRU- value of less than 170 as “good inhibition” or responsiveness. The results 
are also shown in fig 3, where a cut-off point of 170 (corresponding to a 5% percentile of 
PRU) is shown by arrow. 
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After one month on Clopidogrel treatment 
% inhibition results 
Table 4: Distribution of results 
N Valid 88
Missing 2
Mean 41,78
Median 43,00
Std. Deviation 24,661
Percentiles 25 19,00
50 43,00
75 56,75
95 89,20
 
91 patients were randomized to clopidogrel treatment. Due to one failure of recording of % 
inhibition, statistics were performed on n = 90. For 2 patients results were missing due to 
failure of analysis.  
Median % inhibition was 43. Given our cut-off value of 24% defined at baseline, we 
considered all patients with a treatment response with value 24% and less to be non-
responders to clopidogrel. The cumulative percent of non- responders was 28%. The results 
are also shown in fig 4, arrow indicating the cut- off value. 
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PRU- results 
Table 5: Distribution of results 
N Valid 89
Missing 2
Mean 139,60
Median 140,00
Std. Deviation 67,132
Percentiles 25 86,00
50 140,00
75 195,50
95 243,50
 
Median value for PRU after one month was 140. From the statistics performed at baseline the 
cut off value of 170 was defined for non- responsiveness. When we looked at the cumulative 
percent, there were approximately 35% non- responders (having a PRU- value of 170 or 
more). 
Results are also shown in fig 5, arrow indicating the cut- off level. The histogram for PRU 
shows an approximately normal distribution. 
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Changes from baseline to one month on treatment 
The changes in % inhibition are shown in fig. 6, a comparison of the same individuals at 
baseline and after one month on clopidogrel treatment. Median % inhibition changed from 6% 
to 43%.  
 
Fig 6 
 
Changes in PRU from baseline to one month on clopidogrel treatment are shown in fig. 7. 
Decrease in median PRU from 240 to 140.  
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Comparison of the different ways to express the results (PRU and % inhibition) 
The 35% (PRU) - and the 28% (% inhibition) non- responders does not represent a great 
difference. We have checked if the 28% non responders defined by % inhibition, were 
included in the 35% defined by measuring PRU.  
There were 2 individuals who were non- responders with the % inhibition and not with the 
PRU. The other non- responders with % inhibition were all included amongst the 35% non 
responders with PRU.  
 
Discussion  
The aim of our study was to estimate the prevalence of clopidogrel non- responders in a given 
population of patients with CHD. We investigated two variables, PRU and % inhibition, given 
from the VerifyNow screening method.  
 
PRU and % inhibition display close to opposite results: A high PRU value indicates high 
platelet reactivity. This is confirmed by a low % inhibition value.  
At baseline that was exactly what we found. A histogram of PRU showed normal distribution 
of the material.  
This result is reflected in % inhibition, with median value of 6. A low value of % inhibition 
was expected at this point, where no clopidogrel treatment was initiated.  
The 5% percentile of PRU at baseline (PRU1) was close to 170, and we used this as our “cut- 
off- point” corresponding to a commonly used limit with 5% of a reference population being 
regarded as “irregular”. After one month on treatment a PRU value less than 170 were 
regarded as responsiveness to clopidogrel. The equivalent value in % inhibition is the 95% 
percentile which was 24%. Our “reference population” was CHD patients on ASA, thought to 
be relevant. 
 
After one month on clopidogrel treatment new analyses were performed. When applying the 
cut off value on these results, we calculated an estimation of prevalence of non responsiveness 
to clopidogrel for PRU and % inhibition of 35% and 28%, respectively. Comparing the 
individuals in each group we found 2 individuals who were non- responders with the % 
inhibition and not with the PRU. The other non- responders with % inhibition were all 
included amongst the 35% non- responders with PRU. This gives support to the validation of 
the VerifyNow.  
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 The VerifyNow P2Y12 assay is a relatively newly developed method for measuring platelet 
reactivity. A few studies have been performed using this assay, for example the VERITAS- 
study that indicates that the assay is a sensitive device for measuring platelet inhibition with 
clopidogrel (22). Van Werkum et al have compared the VerifyNow Assay to light 
transmittance aggregometry for assessing the inhibitory effects of clopidogrel on platelet 
function. They found a strong correlation between the two methods of measurement looking 
at late aggregation and PRU (20). 
The assay automatically displays the results in PRU, and to retrieve the % inhibition result a 
manual operation has to be performed. There is a possibility of miscalculation of % inhibition 
in the assay. % inhibition is a calculated result, based on analysis in both assay- channels. An 
error in either assay- channel will give a false result.  
Ex vivo platelet function tests do not necessarily give an accurate measurement of in vivo 
platelet function. Other factors (not measured) in vivo may influence platelet reactivity, and 
thrombus formation. Laboratory non- responsiveness may not be the same as clinical non- 
responsiveness and vice versa.  
 
Snoep et al has given a systematic review and performed a meta- analysis on clopidogrel non- 
responsiveness in patients undergoing PCI with stenting (24). They found the mean 
prevalence of laboratory clopidogrel non-responsiveness to be 21%. They also found that 
laboratory non- responsiveness to clopidogrel was associated with “clinical non- 
responsiveness” (increased risk of stent thrombosis and other cardiovascular outcomes). The 
time of blood sampling after loading of clopidogrel could be a reason for differences in 
prevalence of non- responsiveness during clopidogrel treatment. Reported prevalences 
decreased with increasing time to blood sampling after loading. In one study of clopidogrel 
non- responsiveness in patients undergoing elective stenting who received a 300 mg loading 
dose at the time of stenting, 63% of patients were non- responders at 2 hours, approximately 
30% at days 1 and 5 post stenting, and 15% by day 30 on continuous maintenance dosing (7). 
According to Snoep et al the same effect of time on prevalence of non- responders has not 
been shown when a 600mg loading dose has been used, given identical maintenance dosing 
(24).  
 
A 600 mg loading dose of clopidogrel has proved superior to a 300mg loading dose in acute 
disease states. It gives a lower prevalence of non- responders and studies have indicated a 
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lower incidence of cardiovascular events. This needs verifying in prospective studies (6), (24). 
The factor of loading dose does not apply to our study, due to already reached steady- state of 
inhibition after one month on clopidogrel treatment.  
 
There are limited data available to link clopidogrel non- responsiveness to the occurrence of 
thrombotic events (6). The review article of Siller- Matula et al comments the discrepancy 
between the high rate of clopidogrel non- responsiveness (up to 40%), and the corresponding 
quite low overall incidence of acute and subacute stent thrombosis (0,6- 2%) (25). In this 
article they also comment on late stent thrombosis, occurring months after stent implantation. 
Combined antiplatelet therapy is often reduced 6- 12 months after initiation. This has been 
suggested as reason for late thrombosis. The authors suggest pathological mechanisms and 
failure of complete reendothelialization in the vessel walls as main reasons for this 
phenomenon. This hypothesis is strengthened by the observation of thrombosis not 
necessarily occurring immediately after stopping clopidogrel treatment, but up to months later 
(25).   
 
Increased loading dose (600mg) of clopidogrel could reduce the prevalence of non- 
responders to the drug, but not eliminate the problem. Research is ongoing on new 
thienopyridines, not currently on the market. Prasugrel is one of the most promising, and 
phase two studies on healthy volunteers have already been performed with optimistic results.  
Phase one trials on patients with coronary heart disease give similar results. Prasugrel is an 
orally active drug, it is completely converted into its active metabolite, meaning no metabolic 
waste. Prasugrel is up to ten times more potent than clopidogrel. Siller- Matula et al describes 
early data from the phase three study TRITON TIMI 38, which compare clopidogrel with 
prasugrel in STEMI or NSTEMI patients. The results indicate that prasugrel produces a more 
consistent platelet inhibition compared with clopidogrel. In the group treated with clopidogrel 
there was a percentage of non- responders of 22- 43%, whereas in the prasugrel- group there 
were none (3), (25). Recently, the final clinical report from this study indicate improved 
outcome in cardiovascular end- points on the cost of significantly more bleeding episodes 
(26).  
 Finally, the ASCET study (18) will hopefully give additional knowledge about the relation 
between clopidogrel non- responsiveness in the laboratory and relevant clinical end- points.  
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